Swiss drugmaker Roche Holding AG announced Monday it is paying $230 million to take over Anadys Pharmaceuticals Inc., a U.S.-based specialist in the development of hepatitis C treatments.
The offer amounts to $3.70 per share, a premium of more than 250 percent on Anadys's closing price Friday, Roche said.
The board of San Diego-based Anadys approved the deal, which analysts said could boost the company's chances of getting approval for Setrobuvir, an oral drug currently being tested for treatment of chronic infections with hepatitis C virus, or HCV.
"With Roche's considerable capabilities and experience in HCV, this acquisition provides the best chance of success for the new potential treatments our team has been dedicated to developing," Anadys CEO Steve Worland was quoted as saying in a statement.
Roche said the acquisition would boost its portfolio of hepatitis C drugs, which include Pegasys and Copegus.
Last week, the Basel-based company reported third-quarter sales of 9.82 billion Swiss francs ($10.98 billion).
Roche shares were down 0.6 percent at 141.90 francs ($158.00) on the Zurich exchange.
Decision Desk HQ New Hampshire Exit Polling Is Out And It's Wild | RedState
Open thread: The battle for New Hampshire’s silver medal; Update: Fox calls Trump, Sanders winners
'Worth a thousand words': One 'disgraceful' photo sums up Hillary perfectly
Toxic Words | Human Events
Mike Shedlock - European Bloodbath Spills Over to US Markets: Deutsche Bank CoCo Bonds Collapse, Shares at Record Low
After Youtube Terminated His Account Twice, Hickok45 Found A New Home
2016 Election Primary Results